Uncategorized

It’s early days for xenotransplantation, but eGenesis, Eledon, United Therapeutics and more are working to develop solutions to make this approach a viable option and help ease the organ shortage crisis.

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several companies—including Novartis, Scholar Rock and Biogen—progressing novel candidates through clinical trials.

Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of branded biologics looking to maintain blockbuster revenue.

Following big announcements from Lilly and Merck, J&J is pledging $55 billion over the next four years to open new plants.

The final rule, which allows registered clinicians to prescribe up to an initial six-month supply of the drug used to treat opioid use disorder via telehealth, will now go into effect Dec. 31.

Proposed cuts to National Institutes of Health funding threaten a critical pipeline of innovation and discovery necessary to fuel advancements in patient care, according to researchers and provider groups.

The business, acquired by ICU Medical in 2022, has been dealing with a series of recalls and quality issues over the past several years.

Apostar en un casino online ofrece a los jugadores una experiencia emocionante y conveniente desde la comodidad de su hogar. Con una amplia variedad de juegos, promociones atractivas y la posibilidad de jugar en cualquier momento, las plataformas de juegos online han ganado popularidad. Si aú …

The massive PBM is pivoting to a cost-based reimbursement model, which it says will reduce variation in how pharmacies are paid. Pharmacy groups say that depends on the specifics of Optum Rx’s plan.

DispatchHealth CEO Jennifer Webster will lead the combined company once the deal closes, which is expected in mid-2025.